Flohale Rotacaps

Fluticasone Propionate Inhalation
250mg
Cipla Ltd.
Pack size 1
Dispensing mode
Source
Agent
Retail Price 296.83 NPR

Indications

Flohale Rotacaps is used for: Asthma prophylaxis

Adult Dose

Inhalation Asthma prophylaxis Adult: As fluticasone propionate powd or aerosol inhaler: 100 mcg bid in mild asthma, up to 500-1,000 mcg bid in severe cases. Child: 4-16 yr As fluticasone propionate powd or aerosol inhaler: 50-100 mcg bid, increased to 200 mcg bid if necessary.

Child Dose

Inhalation Asthma prophylaxis Child: 4-16 yr As fluticasone propionate powd or aerosol inhaler: 50-100 mcg bid, increased to 200 mcg bid if necessary. <4 years: Safety and efficacy not established

Renal Dose

Administration

Prime inhaler (4 actuations into air) before first use and after prolonged (>7 days) idleness Valve holding chamber and face mask may be used for younger patients

Contra Indications

Hypersensitivity to drug, components or milk proteins, which may result in anaphylaxis, angioedema, rash, and urticaria. Primary treatment of status asthmaticus, acute bronchospasm.

Precautions

Respiratory tract tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, ocular herpes simplex; care must be taken to avoid exposure Nasal septum perforation, epistaxis, wheezing Cataracts, glaucoma, increased intraocular pressure may occur; monitor for glaucoma and cataracts Risk of more serious or fatal course of chickenpox or measles in susceptible patients (eg, unvaccinated or immunologically unexposed individuals); care must be taken to avoid exposure Hypercorticism and adrenal suppression may occur with high dosages or at regular dosage in susceptible individuals; if such changes occur, taper withdrawal gradually May decrease growth velocity in children; monitor growth of pediatric patients Assess for decrease in bone mineral density initially and periodically thereafter Use with caution in immunocompromised patients Prolonged use of corticosteroids may increase incidence of secondary infection Risk of infections of nose and pharynx, including Candida albicans; must rinse mouth after inhalation to reduce risk Excessive use may suppress hypothalamic-pituitary-adrenal function; monitor closely, especially postoperatively or during periods of stress During periods of stress or severe status asthmaticus, supplementary systemic corticosteroids may be immediately required; patient should carry warning card indicating possible need for supplementary systemic steroids in such emergencies Lactation: Fluticasone propionate concentrations in plasma after inhaled therapeutic doses are low; concentrations in human breast milk are likely to be correspondingly low; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child from the drug or from underlying maternal condition

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Fluticasone Propionate Inhalation : >10% Oral candidiasis (<31%),Throat irritation (3-22%),Upper respiratory tract infection (16-18%),Fatigue or malaise (16%),Nasal congestion (16%),Rhinitis (<13%),Musculoskeletal pain (2-12%),Headache (5-11%) 1-10% Nasal congestion (8%),Sinusitis or sinus infection (4-7%),Cough (4-6%),Bronchitis (2-6%),Hoarseness or dysphonia (2-6%),Allergic rhinitis (5%),Nasal discharge (5%),Upper respiratory inflammation (2-5%),Muscle injury (<5%),Gastrointestinal (GI) discomfort or pain (1-4%) Frequency Not Defined Hypersensitivity reactions (including anaphylaxis, angioedema, rash, urticaria) Respiratory: Rhinitis, rhinorrhea or postnasal drip, nasal sinus disorders, laryngitis GI: Diarrhea, loss of taste, viral infections, dyspeptic symptoms, discomfort, pain, hyposalivation Muscular: Musculoskeletal pain, stiffness, tightness, rigidity, injuries, soreness Other: Dizziness, migraine, fever, viral infection, pain, chest symptoms, viral skin infections, soft tissue injuries, urinary infections

Mechanism of Action

Fluticasone utilises a fluorocarbothioate ester linkage at the 17 carbon position. It has potent vasoconstrictive and anti-inflammatory activity, but weak hypothalamic-pituitary-adrenal (HPA) inhibitory effect when applied topically. Fluticasone shown to exhibit anti-inflammatory effect on neutrophils, eosinophils, macrophages, mast cells, lymphocytes, and mediators (histamine, leukotrienes, cytokines, eicosanoids)

Note

Flohale 250mg Rotacaps manufactured by Cipla Ltd.. Its generic name is Fluticasone Propionate Inhalation. Flohale is availble in Nepal. Farmaco Nepal drug index information on Flohale Rotacaps is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Fluticasone Propionate Inhalation :